12/2/2022  9:29:33 PM Chg. +0.125 Volume Bid9:59:58 PM Ask9:59:58 PM Market Capitalization Dividend Y. P/E Ratio
17.785EUR +0.71% 45,681
Turnover: 816,986.465
17.520Bid Size: 600 17.815Ask Size: 600 3.12 bill.EUR 0.00% 13.58

Business description

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology, inflammation and infectious diseases. Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca, Roche and UCB. In addition, the Company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with Boehringer Ingelheim and MedImmune in the field of diabetes, with Janssen Pharmaceuticals in the field of depression and with Roche in the field of Alzheimer's disease.
 

Management board & Supervisory board

CEO
Dr. Werner Lanthaler
Management board
Enno Spillner, Dr. Cord Dohrmann, Dr. Craig Johnstone
Supervisory board
Prof. Dr. Iris Löw-Friedrich, Dr. Constanze Ulmer-Eilfort, Dr. Elaine Sullivan, Dr. Mario Polywka, Kasim Kutay, Roland Sackers
 

Company data

Name: Evotec SE
Address: Essener Bogen 7,D-22419 Hamburg
Phone: +49-40-56081-0
Fax: +49-40-56081-222
E-mail: info@evotec.com
Internet: www.evotec.com
Industry: Biotechnology
Sector: Biotechnology
Sub sector: Biotechnology
End of financial year: 12/31
Free Float: 62.19%
IPO date: 11/10/1999

Investor relations

Name: Volker Braun
IR phone: +49-40-56081-775
IR Fax: -
IR e-mail: investorrelations@evotec.com

Main Shareholders

Freefloat
 
62.19%
T. Rowe Price Group, Inc.
 
10.00%
Novo A/S
 
9.98%
DWS Investment GmbH
 
4.97%
BlackRock, Inc.
 
3.02%
Impax Asset Management Group plc
 
3.00%
Allianz Global Investors Europe GmbH
 
3.00%
The Goldman Sachs Group, Inc.
 
2.21%
Roland Oetker / ROI Verwaltungsgesellschaft
 
1.64%